

The strange case: the unsymmetric cisplatin-based Pt(IV) prodrug [Pt(CH₃COO)Cl₂(NH₃)₂(OH)] exhibits higher cytotoxic activity with respect to its symmetric congeners due to carrier-mediated cellular uptake

Elisabetta Gabano,¹ Ilaria Zanellato,² Giulia Pinton,³ Laura Moro,³ Mauro Ravera,² and Domenico Osella,²

¹ *Dipartimento per lo Sviluppo Sostenibile e la Transizione Ecologica, Università del Piemonte Orientale, Piazza Sant'Eusebio 5, 13100 Vercelli (Italy)*

² *Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Michel 11, 15121 Alessandria (Italy)*

³ *Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Via Bovio 6, 28100 Novara (Italy)*

Correspondence should be addressed to Mauro Ravera; mauro.ravera@uniupo.it and Domenico Osella; domenico.osella@uniupo.it

SUPPLEMENTARY MATERIAL

- Figure S1** Sketch of the complexes under investigation.
- Figure S2** [¹H, ¹⁵N] HSQC spectrum of ¹⁵N-1.
- Figure S3** [¹H, ¹⁵N] HSQC spectrum of ¹⁵N-1 after 2 h reduction in cell cytosol.
- Figure S4** [¹H, ¹⁵N] HSQC spectrum of ¹⁵N-2.
- Figure S5** [¹H, ¹⁵N] HSQC spectrum of ¹⁵N-2 after 2 h reduction in cell cytosol.
- Figure S6** [¹H, ¹⁵N] HSQC spectrum of ¹⁵N-2 after 2 h reduction in cell cytosol (magnification).
- Figure S7** [¹H, ¹⁵N] HSQC spectrum of ¹⁵N-3.
- Figure S8** [¹H, ¹⁵N] HSQC spectrum of ¹⁵N-3 after 2 h reduction in cell cytosol.
- Figure S9** [¹H, ¹⁵N] HSQC spectrum of ¹⁵N-3 after 2 h reduction in cell cytosol (magnification).
- Figure S10** Accumulation ratio (AR) in A2780 cells treated for 1 h with **1-3** in the absence or in the presence of cimetidine.
- Figure S11** RP-HPLC chromatograms of **3** (100 μM) aged in complete RPMI 1640 at time zero and after 72 h in solution.
- Figure S12** (A) RP-HPLC chromatograms of **2** aged in RPMI 1640 at time zero and after 72 h in solution. (B) ESI-MS spectra of **2** and [**2**-Cl+H₂O]⁺. (C) Zoomed-in version of (A).




Figure S1 Sketch of the complexes under investigation.

Synthesis of the $^{15}\text{NH}_3$ -labeled complexes $^{15}\text{N-1}$, $^{15}\text{N-2}$, and $^{15}\text{N-3}$.

The syntheses of ^{15}N -labeled complexes started with the preparation of *cis*-[PtCl₂($^{15}\text{NH}_3$)₂] as previously reported. ^{15}N -cisplatin was then oxidised with hydrogen peroxide in water to get the dihydroxido complex $^{15}\text{N-1}$ (with a microwave-assisted heating) or in acetic acid to get the monoacetato complex $^{15}\text{N-2}$. Finally, the diacetato complex $^{15}\text{N-3}$ was obtained from the reaction between $^{15}\text{N-1}$ and acetic anhydride.

$^{15}\text{N-1}$. Yield: 90 %. ^{15}N NMR (50.70 MHz, H₂O/D₂O 9/1): δ -33.8 ppm with satellite peaks at -31.2 ppm and -36.6 ppm ($^1J_{\text{Pt-N}} = 274$ Hz and $^2J_{\text{Pt-H}} = 52$ Hz). ESI-MS (positive ion mode): 336 *m/z* [M+H]⁺. Calc. for [Cl₂H₉ $^{15}\text{N}_2\text{O}_2\text{Pt}$]⁺ 336 *m/z* [M+H]⁺.

$^{15}\text{N-2}$. Yield: 85 %. ^{15}N NMR (50.70 MHz, H₂O/D₂O 9/1): δ -35.6 ppm with satellite peaks at -32.9 ppm and -38.2 ppm ($^1J_{\text{Pt-N}} = 273$ Hz and $^2J_{\text{Pt-H}} = 54$ Hz). ESI-MS (positive ion mode): 379 *m/z* [M+H]⁺. Calc. for [C₂H₁₁Cl₂ $^{15}\text{N}_2\text{O}_3\text{Pt}$]⁺ 379 *m/z* [M+H]⁺.

$^{15}\text{N-3}$. Yield: 80 %. ^{15}N NMR (50.70 MHz, H₂O/D₂O 9/1): δ -39.6 ppm with satellite peaks at -37.0 ppm and -42.5 ppm ($^1J_{\text{Pt-N}} = 265$ Hz and $^2J_{\text{Pt-H}} = 54$ Hz). ESI-MS (negative ion mode): 418 *m/z* [M-H]⁻. Calc. for [C₄H₁₁Cl₂ $^{15}\text{N}_2\text{O}_4\text{Pt}$]⁻ 418 *m/z* [M-H]⁻.




Figure S2 [^1H , ^{15}N] HSQC spectrum of ^{15}N -1 in $\text{H}_2\text{O}/\text{D}_2\text{O}$ 9/1.




Figure S3 [^1H , ^{15}N] HSQC spectrum of ^{15}N -1 after 2 h reduction in cell cytosol.




Figure S4 $[^1\text{H}, ^{15}\text{N}]$ HSQC spectrum of ^{15}N -2 in $\text{H}_2\text{O}/\text{D}_2\text{O}$ 9/1.




Figure S5 $[^1\text{H}, ^{15}\text{N}]$ HSQC spectrum of ^{15}N -2 after 2 h reduction in cell cytosol.




Figure S6 [^1H , ^{15}N] HSQC spectrum of ^{15}N -2 after 2 h reduction in cell cytosol (magnification).




Figure S7 [^1H , ^{15}N] HSQC spectrum of ^{15}N -3 in $\text{H}_2\text{O}/\text{D}_2\text{O}$ 9/1.




Figure S8 [¹H, ¹⁵N] HSQC spectrum of ¹⁵N-3 after 2 h reduction in cell cytosol.




Figure S9 [¹H, ¹⁵N] HSQC spectrum of ¹⁵N-3 after 2 h reduction in cell cytosol (magnification).




Figure S10 Accumulation ratio (AR) in A2780 cells treated for 1 h with **1-3** (10 μ M) in the absence (gray bars) or in the presence (white bars) of cimetidine (CMT, co-treatment, 1.5 mM). Data are the mean \pm sd of three independent replicates and were compared using one-way analysis of variance (ANOVA) with Tukey post-hoc test. Statistical analysis (in presence vs. in absence of CMT): no indication = not significant; ***p < 0.001).




Figure S11 RP-HPLC chromatograms of **3** (100 μM) aged in complete RPMI 1640 medium at time zero and after 72 h in solution.




Figure S12 (A) RP-HPLC chromatograms of **2** (100 μ M) aged in complete RPMI 1640 medium at time zero and after 72 h in solution. In the gray box, the two peaks belonging to **2** and its hydrolyzed derivative $[\mathbf{2}\text{-Cl}+\text{H}_2\text{O}]^+$ are present. (B) ESI-MS spectra of **2** and $[\mathbf{2}\text{-Cl}+\text{H}_2\text{O}]^+$. (C) Zoomed-in version of A in the gray box area containing the chromatograms at $t = 0$ and 72 h, and those obtained at intermediate aging times. (Note: the peaks below 0.10 AU intensity belong to the medium, and partially overlap the peaks of interest, but the hyphenated technique permits identification of the Pt species).